Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
about
Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspectivePI3K/Akt/mTOR inhibitors in breast cancerPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerAn Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic ReviewOptimal management of hormone receptor positive metastatic breast cancer in 2016Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast CancerTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsManagement of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment optionsClinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerPI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancerUse of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomesTargeting translation initiation in breast cancerJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesRecent developments and translational aspects in targeted therapy for metastatic breast cancerBridging the gap between clinicians and systems biologists: from network biology to translational biomedical researchReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantEnhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling PathwaysAttributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Novel Strategies to Improve the Endocrine Therapy of Breast Cancer.The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancerThe PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trialsOvercoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells.Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.Targeted therapies for ER+/HER2- metastatic breast cancer.Molecular mechanisms regulating the hormone sensitivity of breast cancer.Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Targeted cancer therapy--are the days of systemic chemotherapy numbered?Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsAutophagy regulation in the development and treatment of breast cancerEmerging therapeutic targets in metastatic progression: A focus on breast cancer.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
P2860
Q26752834-07B813CD-B04F-4223-93A8-29E0C2532F69Q26771394-373D5D58-B827-433B-9783-BF158616B2E9Q26775361-FE29EB56-8905-413C-9510-E49BF3EE7380Q26777085-FB752DC5-C16E-4751-8D74-3AFEBC795A43Q26777683-5D6E1C39-382D-48B1-8E09-A4907805CD4EQ26777734-8D371334-4C50-477F-9047-F89A0EB72F5AQ26785496-15A3FAEA-F124-4017-9DE0-C3745A071D0FQ26851417-DD190ED0-7E09-46DF-8BC2-1DE7729C9A70Q26995549-0D36889D-AEC3-4B12-9AFA-2FCF3B16658BQ27001170-D581F9A9-5E8D-454C-AE79-D406720DFF30Q27001260-0C102AB1-1A3C-4704-A246-897D39135B85Q27006181-6E66AC70-775E-4143-83C5-E6C4AAFB9EECQ27009257-2B94BA85-E2DB-4D3B-B6E6-28D7BFD993ACQ27027284-08480E45-B726-43D5-BEC5-527C9EACD916Q28071388-24EAE4DB-ABAD-448D-AC78-79CD9C7D0726Q28072755-980D1364-7278-4DF6-81C8-F4ABA256B1EFQ28072766-724A62C1-02F2-4941-886C-5C8D6984D543Q28076777-58A0EF3B-CD60-49C4-9471-DEB235B0AD88Q28084585-EC8114BA-6884-4183-8AEA-9B750272EFD0Q30243969-EB92498B-48B2-41DF-A851-8F48119AC2F2Q30317569-2563DB59-9912-4AC2-B2BA-D7D0A13978D5Q33656801-1D9FD8D7-B8E2-440F-83CC-EA2A0C421873Q33727284-3D949480-7088-4699-A2A5-5B61F33C4238Q33862290-B60D9B62-26FE-45FB-8E66-55DA4B5B8402Q33937368-3C1F9895-A46F-41C9-BCD2-A39B64BC645DQ33961949-204F7192-3197-4FE3-B194-AEA7BF63F536Q34103963-CEF7A8DD-7BD2-4D07-AACE-8A082749687BQ34352887-E10A4BFD-322E-4997-B1D0-2E2D1968F1E2Q34547982-5FA7A895-AE04-49B1-895E-01B52B24EB74Q34657786-94CCC795-EC75-45C1-84C8-784F1836ECB9Q35079440-1ACD4C9B-FCE0-4FBC-9ED6-37594148425CQ35631641-9CF2854D-0FB2-4AF3-8531-54FC0CBBC341Q35658860-7F38F079-2D2E-4050-A428-F8A75D0ADBBDQ35713360-4B72F313-5548-4840-9BBD-18FEC13916B9Q35958082-42EF6273-9DA7-4EA6-AA56-01913CE8C0BFQ36174805-328D600D-AF74-4C4C-85DF-0AAA2152E180Q36273796-6694B1BA-C6B8-4BE1-A186-3E633AAD5A6CQ36398762-609FDDD4-9D07-4997-AFFD-E5AA1EEC1343Q36854062-33BF062F-A771-4F6C-9B6C-2EB269FC664EQ36946008-DAFD7CD4-63E9-402D-BFEB-253733F977FB
P2860
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@ast
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@en
type
label
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@ast
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@en
prefLabel
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@ast
Randomized phase III placebo-c ...... d or metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Randomized phase III placebo-c ...... ed or metastatic breast cancer
@en
P2093
Andrew Strahs
Ann A Lazar
Anna Berkenblit
Arlene Chan
August M Garin
Daniel F Hayes
Laurence Moore
Lih Lisa Kang
Louis Chow
Maria Cincotta
P2860
P304
P356
10.1200/JCO.2011.38.3331
P407
P577
2012-12-10T00:00:00Z